论文部分内容阅读
目的:观察沙美特罗/丙酸氟替卡松(舒利迭)联合茶碱治疗高海拔地区(平均海拔2 295m)慢性阻塞性肺疾病(COPD)的临床疗效。方法:选取80例COPD患者作为研究对象,随机分成对照组和研究组各40例,两组患者口服茶碱缓释胶囊0.2 g,2次/日。研究组加用舒利迭(沙美特罗替卡松50mg/250mg),2次/日,治疗前后分别对两组进行肺功能、血气分析、呼吸困难评分进行分析。结果:经过12周治疗后,研究组血气中PaO2含量明显高于对照组,血气中PaCO2明显低于对照组,血气中SaO2高于对照组,差异均有统计学意义(P<0.05)。研究组肺功能指标FVC、FEV1、FEV1/FVC%均高于对照组,研究组的呼吸困难评分下降值是(0.73±0.58)分,对照组是(0.35±0.62)分,差异有统计学意义(P<0.05)。结论:沙美特罗/丙酸氟替卡松联合茶碱缓释胶囊治疗COPD能有效减轻患者的临床症状,改善血气及肺功能,安全可靠,具有重要的临床应用价值。
Objective: To observe the clinical efficacy of salmeterol / fluticasone propionate combined with theophylline in the treatment of chronic obstructive pulmonary disease (COPD) at high altitude (mean height 2 295m). Methods: Eighty COPD patients were selected as study subjects and randomly divided into control group and study group, 40 cases each. The two groups were given 0.2 g, 2 g / day of theophylline sustained-release capsules. The study group was given seretide (salmeterol / fluticasone 50mg / 250mg), 2 times / day, respectively, before and after treatment of lung function, blood gas analysis, dyspnea score analysis. Results: After 12 weeks of treatment, PaO2 in the study group was significantly higher than that in the control group. The PaCO2 in the blood was significantly lower than that in the control group, and the SaO2 in the blood was higher than that in the control group (P <0.05). The lung function indexes FVC, FEV1, FEV1 / FVC% of the study group were higher than those of the control group, the decrease of the dyspnea score was (0.73 ± 0.58) in the study group and (0.35 ± 0.62) in the control group, the difference was statistically significant (P <0.05). Conclusion: Salmeterol / fluticasone propionate combined with theophylline sustained release capsules in the treatment of COPD can effectively reduce the clinical symptoms, improve blood gas and pulmonary function, safe and reliable, and has important clinical value.